ALPMY - Astellas Pharma partners with YASKAWA for innovative cell therapy
2024-05-21 06:38:46 ET
More on Astellas Pharma
- Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance
- Pfizer, Astellas first-line bladder cancer therapy accepted for review in China
- Seeking Alpha’s Quant Rating on Astellas Pharma ADR
- Historical earnings data for Astellas Pharma ADR